APLS240517P55000
- 13.70
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Apellis Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Apellis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/23/2024 9.92% Wells Fargo $57 → $48 Maintains Equal-Weight 05/08/2024 37.39% Citigroup $67 → $60 Mainta
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $48
Wells Fargo analyst Derek Archila maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $57 to $48.According to TipRanks data, the analyst has a success ra
Express News | Apellis Pharmaceuticals Inc : Wells Fargo Cuts Target Price to $48 From $57
Express News | Apellis Pharmaceuticals Inc : Raymond James Cuts Target Price to $111 From $116
Unusual Options Activity: LCID, APLS and Others Attract Market Bets, LCID V/OI Ratio Reaches 199.4
EST May 16th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
Apellis Pharmaceuticals: A Strong Buy on Syfovre's Performance and Market Potential
Express News | Apellis: New Senior Secured Credit Facility Matures on May 13, 2030
Express News | Apellis Eliminates $366 Million Payment Obligations
Express News | Apellis Pharmaceuticals Refinances Existing Debt With up to $475 Million Non-Dilutive Credit Facility From Sixth Street
Apellis Pharmaceuticals Refinances Existing Debt With Up to $475 Million Non-Dilutive Credit Facility From Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Sign
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals(APLS.US) Officer Sells US$3.34 Million in Common Stock
$Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal sold 78,907 shares of common stock on May 8, 2024 at an average price of $42.3517 for a total value of $3.34 million.Source: Announcement
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Pascal Deschatelets, Chief Scientific Officer, on May 08, 2024, sold 78,907 shares in Apellis Pharmaceuticals (APLS) for $3,341,848. Following the Form 4 filing with the SEC, Deschatelets has control
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Apellis Pharmaceuticals, Inc., a commerci
Form 144 | Apellis Pharmaceuticals(APLS.US) Officer Proposes to Sell 3.34 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal intends to sell 78,907 shares of its common stock on May 8, with a total market value of approximately $3.
Apellis Pharmaceuticals Price Target Cut to $60.00/Share From $67.00 by Citigroup
Apellis Pharmaceuticals Price Target Cut to $60.00/Share From $67.00 by Citigroup
Apellis Pharmaceuticals Is Maintained at Buy by Citigroup
Apellis Pharmaceuticals Is Maintained at Buy by Citigroup